Status:
UNKNOWN
Ceftolozane-tazobactam for the Treatment of Respiratory Infections Due to Extensively Drug-resistant Pseudomonas Aeruginosa Among Critically Ill Patients: a Retrospective Study.
Lead Sponsor:
Semmelweis University
Conditions:
Ventilator Associated Pneumonia
Antibiotic Resistant Infection
Eligibility:
All Genders
16-90 years
Brief Summary
The aim of this study is to report our experience with ceftolozane-tazobactam and to evaluate its safety and efficacy in the treatment of ICU dependent nosocomial respiratory tract infections due to e...
Detailed Description
Ceftolozane-tazobactam (C/T) is a novel type of beta-lactam/beta-lactamase inhibitor antibiotics targeting nosocomial infections caused by Gram-negative bacteria. In recent years, ceftolozane-tazobact...
Eligibility Criteria
Inclusion
- Hospital-acquired pneumonia caused by extensively drug-resistant Pseudomonas aeruginosa
- ≥ 72 hours of targeted antibiotic therapy against Pseudomonas aeruginosa with either Colomycin or Ceftolozane-Tazobactam
Exclusion
- Participation in an interventional trial aiming nosocomial infections
- Treatment was not with the intent to cure the infection
Key Trial Info
Start Date :
January 18 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 19 2020
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT04352855
Start Date
January 18 2018
End Date
May 19 2020
Last Update
April 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Semmelweis University
Budapest, Hungary, 1085